Why the study?
Effective treatment of arterial hypertension prevents or delays chronic heart failure, yet population-level effectiveness of antihypertensive therapy remains low. This review systematizes evidence on combined azilsartan medoxomil and chlorthalidone in patients with or at high risk of chronic heart failure.
Does combination therapy with azilsartan medoxomil and chlorthalidone prevent or delay the development of chronic heart failure in patients with arterial hypertension?
Does combination therapy with azilsartan medoxomil and chlorthalidone prevent or delay the development of chronic heart failure in patients with arterial hypertension?
This review summarizes existing studies on the combination of azilsartan medoxomil and chlorthalidone for managing hypertension in patients with or at high risk for chronic heart failure.
Supports azilsartan-chlorthalidone for hypertension control in HF-risk patients; leaves open prospective trials on HF prevention.
Effective treatment of arterial hypertension (AH) is important for preventing or delaying the development of chronic heart failure (CHF) and reducing associated hospitalizations and mortality. Despite the proven benefits of AH control, epidemiological data demonstrate that the effectiveness of antihypertensive therapy remains low at the population level. Combination therapy at the start of hypertension treatment is recommended for the majority of patients, and the combination of an angiotensin II receptor blocker and a diuretic is one of the most rational choices. This review systematizes studies on the use of azilsartan medoxomil with chlorthalidone in patients with CHF or at high risk of its development.
No takes yet. Share an insight, caveat, or question.
Жиров et al. (2026) conducted a review in Arterial hypertension and chronic heart failure. Azilsartan medoxomil with chlorthalidone was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: